Contineum Therapeutics (CTNM) PT Raised to $32 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Contineum Therapeutics (NASDAQ: CTNM) to $32.00 (from $30.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
